EX-16.1 2 tm2220555d1_ex16-1.htm EXHIBIT 16.1

Exhibit 16.1

 

July 7, 2022

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by First Wave BioPharma, Inc. under Item 4.01 of its Form 8-K dated July 5, 2022. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of First Wave BioPharma, Inc. contained therein.

 

Very truly yours,

 

/s/ Marcum llp

 

Marcum llp